Clinical Trials Logo

Filter by:
NCT ID: NCT00552058 Completed - Crohn Disease Clinical Trials

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Start date: March 2008
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.

NCT ID: NCT00552045 Completed - Epilepsy Clinical Trials

Epilepsy Phenome/Genome Project

EPGP
Start date: November 2007
Phase:
Study type: Observational

The purpose of this study is to collect detailed information about the characteristics and genetics of a large number of individuals with epilepsy.

NCT ID: NCT00551473 Completed - Clinical trials for Gastroesophageal Reflux Disease

Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

Start date: May 2007
Phase: Phase 1
Study type: Interventional

Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression. Clinical data on lavoltidine demonstrates a rapid onset of action, high potency, and prolonged duration of effect after single dose. Since tolerance to the class of compounds to which lavoltidine belongs may be dose dependent, the current study is designed to determine if 40mg lavoltdine given for 7days develops tolerance.

NCT ID: NCT00551343 Completed - Clinical trials for Prader-Willi Syndrome

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Start date: October 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

NCT ID: NCT00551304 Completed - Clinical trials for End Stage Renal Disease

Native Kidney Denervation in Patients With End Stage Renal Disease

Start date: October 2007
Phase: Phase 1
Study type: Interventional

To investigate the utility of renal denervation in the treatment of patients with End Stage Renal Disease (ESRD).

NCT ID: NCT00551174 Completed - Clinical trials for Post-Menopausal Osteoporosis

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

Start date: October 2004
Phase: Phase 4
Study type: Interventional

This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received Bonviva either 2 mg IV every 2 months, or 3 mg IV every 3 months. Patients also received daily supplementation with vitamin D and calcium. The anticipated time on study treatment was 2+ years, and the target sample size was 500+ individuals.

NCT ID: NCT00551135 Completed - Pain, Postoperative Clinical Trials

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.

NCT ID: NCT00549497 Completed - Asthma Clinical Trials

A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers

Start date: September 2007
Phase: Phase 1
Study type: Interventional

GW870086X is a novel inhaled steroid that has an improved safety profile over other steroids but is also less potent. This study will look at higher doses to confirm the improved safety profile.

NCT ID: NCT00548808 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study for Type 2 Diabetic Patients

Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level

NCT ID: NCT00548405 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

CARE-MS II
Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.